scholarly journals Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

2013 ◽  
pp. 425 ◽  
Author(s):  
Erminia Ridolo ◽  
Montagni ◽  
Olivieri ◽  
Riario-Sforza ◽  
Cristoforo Incorvaia
Keyword(s):  
Beta 2 ◽  
Long Acting

THYROID STIMULATORS AND THYROID STIMULATION

1971 ◽  
Vol 66 (3) ◽  
pp. 558-576 ◽  
Author(s):  
Gerald Burke
Keyword(s):  
Regulatory System ◽  
Control Site ◽  
Thyroid Cell ◽  
Primary Control ◽  
Physico Chemical ◽  
Site Of Action ◽  
Long Acting

ABSTRACT A long-acting thyroid stimulator (LATS), distinct from pituitary thyrotrophin (TSH), is found in the serum of some patients with Graves' disease. Despite the marked physico-chemical and immunologic differences between the two stimulators, both in vivo and in vitro studies indicate that LATS and TSH act on the same thyroidal site(s) and that such stimulation does not require penetration of the thyroid cell. Although resorption of colloid and secretion of thyroid hormone are early responses to both TSH and LATS, available evidence reveals no basic metabolic pathway which must be activated by these hormones in order for iodination reactions to occur. Cyclic 3′, 5′-AMP appears to mediate TSH and LATS effects on iodination reactions but the role of this compound in activating thyroidal intermediary metabolism is less clear. Based on the evidence reviewed herein, it is suggested that the primary site of action of thyroid stimulators is at the cell membrane and that beyond the(se) primary control site(s), there exists a multifaceted regulatory system for thyroid hormonogenesis and cell growth.

scholarly journals What Is the Role of Long-Acting Neuromuscular Blocking Agents in Modern Adult Cardiac Surgery?

2016 ◽  
Vol 30 (5) ◽  
pp. e45-e46
Author(s):  
Marina Pieri ◽  
Alessandro Belletti ◽  
Giovanni Affronti ◽  
Veronica Dalessandro ◽  
Ada Carla Alba ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Blocking Agents ◽  
Long Acting ◽  
Adult Cardiac Surgery

Effect of a central CRF antagonist on cardiovascular and thermoregulatory responses induced by stress or IL-1 beta

1993 ◽  
Vol 265 (4) ◽  
pp. R834-R839 ◽  
Author(s):  
T. Nakamori ◽  
A. Morimoto ◽  
N. Murakami
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Interleukin 1 ◽  
Corticotropin Releasing Factor ◽  
Mild Stress ◽  
Induced Responses ◽  
Interleukin 1 Beta ◽  
The Central Nervous System ◽  
Beta 2

We investigated the role of central corticotropin-releasing factor (CRF) in the development of cardiovascular and thermal responses induced by stress or by interleukin-1 beta (IL-1 beta) in free-moving rats. Intracerebroventricular (icv) injection of alpha-helical CRF9-41 (10 micrograms), a CRF receptor antagonist, significantly attenuated hypertension, tachycardia, and a rise in body temperature induced by cage-switch stress, a mild stress. However, icv injection of alpha-helical CRF9-41 (10 micrograms) had no effect on hypertension, tachycardia, or fever induced by intraperitoneal (ip) injection of IL-1 beta (2 micrograms/kg) or icv prostaglandin E2 (PGE2, 100 ng). In contrast, icv injection of alpha-helical CRF9-41 (10 micrograms) significantly attenuated hypertension, tachycardia, or fever induced by icv injection of IL-1 beta (20 ng). The present results suggest that central CRF has an important role in the development of the cage-switch stress-induced responses, but it does not seem to contribute to the hypertension, tachycardia, and fever induced by ip IL-1 beta or by central PGE2. However, it is possible that when IL-1 beta directly acts on the central nervous system, some of its actions are mediated by central CRF.

Treatment of Antidepressant-Resistant Bulimia with Naltrexone

1987 ◽  
Vol 16 (4) ◽  
pp. 305-309 ◽  
Author(s):  
Jeffrey M. Jonas ◽  
Mark S. Gold
Keyword(s):  
Eating Disorders ◽  
Preliminary Data ◽  
Endogenous Opioids ◽  
Opiate Antagonist ◽  
Percent Reduction ◽  
Bulimic Symptoms ◽  
Long Acting ◽  
Insight Into

Ten individuals with antidepressant-resistant bulimia were treated with the long-acting opiate antagonist naltrexone. Seven of the ten experienced at least a 75 percent reduction of their bulimic symptoms, and have maintained their improvment on three to five month follow-up. These preliminary data suggest that naltrexone may be of use in bulimia unresponsive to standard antidepressant therapy, and may provide insight into the role of endogenous opioids in the etiology of eating disorders.

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD

2017 ◽  
Vol 22 (3) ◽  
pp. 285-299 ◽  
Author(s):  
Thomas J. Monaco ◽  
Nicola A. Hanania
Keyword(s):  
Adrenoceptor Agonists ◽  
Beta 2 ◽  
Long Acting

scholarly journals The Role of Beta-2-Adrenomediated Mechanisms of Injures of Venous Cerebral Blood Flow in Newborn Rats with Intracranial Hemorrhage

2015 ◽  
Vol 15 (2) ◽  
pp. 93-97
Author(s):  
Oksana Valerievna Semyachkina-Glushkovskaya ◽  
◽  
Marya Vasylievna Ulanova ◽  
Arkady Sergeevich Abdurashitov ◽  
Artemii Sergeevich Gekaluk ◽  
...  
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Intracranial Hemorrhage ◽  
Newborn Rats ◽  
Beta 2

The complementary role of glucocorticosteroids and long-acting β-adrenergic agonists

Allergy ◽  
1998 ◽  
Vol 53 ◽  
pp. 7-13 ◽  
Author(s):  
K. F. Chung
Keyword(s):  
Adrenergic Agonists ◽  
Complementary Role ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document